 H.C. Wainwright said that Altimmune Inc NASDAQ:ALT reported positive Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients. However, shares dropped, which he sees primarily because one patient experienced elevated ALT levels that resolved after a pause in dosing. 